Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer

Clinical trial NCT06693024 · RECRUITING

Trial details

NCT number: NCT06693024
Sponsor: Shu Wang
Status: RECRUITING
Study type: OBSERVATIONAL

HER2-positive Breast Cancer

Start date: 2019-01-01
Primary completion: 2031-12-31
Enrollment: 2806

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.